Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

Genoss DES in Patients With a High Risk of Ischemic Events (GENTLE Registry)

Recruiting

Conditions: Drug-eluting Stent
Coronary Artery Disease

Interventions: Device: Genoss DES

First Posted Date: 2022-07-07

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 200

Registration Number: NCT05448625

Locations: 🇰🇷
Yongin Severance Hospital, Yongin, Gyeonggi-do, Korea, Republic of

Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer

Not Applicable

Recruiting

Conditions: Recurrent Epithelial Ovarian Cancer

Interventions: Other: Standard salvage therapy
Radiation: Standard salvage therapy + SABR

First Posted Date: 2022-07-05

Last Posted Date: 2023-11-24

Lead Sponsor: Yonsei University

Target Recruit Count: 270

Registration Number: NCT05444270

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor

Phase 2

Not yet recruiting

Conditions: Acral Melanoma
Mucosal Melanoma

Interventions: Drug: Pembrolizumab, Vactosertib

First Posted Date: 2022-06-29

Last Posted Date: 2022-06-29

Lead Sponsor: Yonsei University

Target Recruit Count: 30

Registration Number: NCT05436990

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Continuous Distal Adductor Canal Block With Periarticular Local Anesthetic Infiltration Versus Continuous Distal Adductor Canal Block Alone for Analgesia After Total Knee Arthroplasty

Not Applicable

Recruiting

Conditions: Degenerative Osteoarthritis

Interventions: Procedure: Distal adductor canal block and Periarticular block
Procedure: Distal adductor canal block

First Posted Date: 2022-06-22

Last Posted Date: 2024-01-11

Lead Sponsor: Yonsei University

Target Recruit Count: 66

Registration Number: NCT05427019

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Diastolic Hyperemia-Free Ratio in Patients With CAD

Completed

Conditions: Coronary Artery Disease
Coronary Stenosis

First Posted Date: 2022-06-16

Last Posted Date: 2024-03-15

Lead Sponsor: Yonsei University

Target Recruit Count: 300

Registration Number: NCT05421169

Locations: 🇰🇷
Yongin Severance Hospital, Yongin, Gyeonggi-do, Korea, Republic of

Effect of Exercise on Bowel Function in Colorectal Cancer Survivors

Not Applicable

Completed

Conditions: Low Anterior Resection Syndrome
Colorectal Cancer

Interventions: Behavioral: exercise

First Posted Date: 2022-06-15

Last Posted Date: 2024-07-05

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT05420870

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

The Current Status and Clinical OUTcomes of Cardiogenic Shock Patients And the Role of Specialist in Cardiovascular Critical Care Unit

Recruiting

Conditions: Cardiogenic Shock

First Posted Date: 2022-06-13

Last Posted Date: 2022-06-13

Lead Sponsor: Yonsei University

Target Recruit Count: 10000

Registration Number: NCT05415332

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Phase 2

Recruiting

Conditions: PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Interventions: Drug: Orevogomab+PLD
Drug: Orevogomab+Paclitaxel

First Posted Date: 2022-06-07

Last Posted Date: 2023-05-24

Lead Sponsor: Yonsei University

Target Recruit Count: 56

Registration Number: NCT05407584

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Phase 1

Completed

Conditions: Gastric Cancer

Interventions: Drug: Variltinib, Paclitaxel

First Posted Date: 2022-06-02

Last Posted Date: 2023-11-13

Lead Sponsor: Yonsei University

Target Recruit Count: 27

Registration Number: NCT05400915

Locations: 🇰🇷
Yonsei University Health System, Yonsei Cancer Center, Seoul, Korea, Republic of

A Prospective Cohort Study for Establishing Clinical Excellence in Patients With Newly Diagnosed Type 1 and Type 2 Diabetes and Prediabetes

Not yet recruiting

Conditions: Newly Diagnosed Type 1 and Type 2 Diabetes and Prediabetes

First Posted Date: 2022-06-02

Last Posted Date: 2022-06-02

Lead Sponsor: Yonsei University

Target Recruit Count: 3000

Registration Number: NCT05401708

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy